US cost effectiveness of darunavir/ritonavir 600/100mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN trial

PharmacoEconomics

Volumn 28, Issue SUPPL. 1, 2010, Pages 129-146

  Brogan, Anita ^a   Mauskopf, Josephine ^a   Talbird, Sandra E ^a   Smets, Erik ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; TIPRANAVIR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HIDDEN MARKOV MODEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESISTANCE ASSOCIATED MUTATION; SURVIVAL RATE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; HEALTH CARE COSTS; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RITONAVIR; SULFONAMIDES; TIME FACTORS; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 78650733607     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587490-000000000-00000     Document Type: Article

References (74)

1. Braithwaite RS, Justice AC, Chang CC, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 2005; 118: 890-8
2. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: Evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006; 43: 451-7
3. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990-7
4. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19
5. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35
6. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of anti-retrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA study group. J Infect Dis 2004; 190: 1947-56
7. Sabin CA, Scullard G, Easterbrook P, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: Multicentre cohort study. BMJ 2005; 330: 695-9
8. European AIDS Clinical Society (EACS). 2009 guidelines for the clinical management and treatment of HIV infected adults in Europe; 2009 [online]. Available from URL: Http://www.europeanaidsclinicalsociety.org/guidelinespdf/ EACS-EuroGuidelines2009FullVersion.pdf [Accessed 2009 Dec 10]
9. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association guidelines for treatment of HIV-infected adults with antiretroviral therapy, 2006. HIV Med 2006; 7: 487-503
10. US Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents (USDHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2008 Jan 29 [online]. Available from URL: Http://AIDSinfo.nih.gov [Accessed 2009 Dec 10]
11. DeJesus E, LaMarca A, Sension M, et al. The CONTEXT study: Efficacy and safety of GW433908/r in PI-experienced subjects with virological failure (24 week results) [abstract 178]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-13; Boston, MA, USA
12. Dragsted UB, Gerstoft J, YouleM, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: The MaxCmin2 trial. Antivir Ther 2005; 10: 735-43
13. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised noninferiority trial. Lancet 2006; 368: 476-82
14. Johnson MA, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 685-94
15. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-46
16. Madruga JV, Berger D, McMurchi M, et al. Efficacy and safety of darunavir/ritonavir compared with that of lopinavir/ritonavir at 48 weeks in treatment-experienced, HIV infected patients in TITAN: A randomized controlled phase III trial. Lancet 2007; 370: 49-58
17. International AIDS Society USA (IAS-USA). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296: 827-43
18. Berger DS, Northland R, Scribner A, et al. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at week 48 in TITAN [abstract P7.3/27]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid, Spain
19. Tibotec Pharmaceuticals. Results of TITAN Phase III clinical trial for darunavir/r. City: Mechelen, Belgium. Tibotec Pharmaceuticals. Data on file, 2007
20. Gallant JE. Approach to the treatment-experienced patient. Infect Dis Clin North Am 2007; 21: 85-102
21. Mauskopf J, Brogan A, Martin S, et al. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. PharmacoEconomics 2010; 28 Suppl. 1: 83-105
22. Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression: The T cell in HIV infection and disease. Curr Opin HIV AIDS 2006; 1: 43-9
23. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
24. Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV health care in the HAART era [abstract 537]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver, Colorado, USA
25. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5: 294-304
26. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA Study: An observational study. Lancet 2003; 362: 22-9
27. Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: A comparison with the general population. AIDS 2004; 18: 89-97
28. Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16: 201-7
29. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to
30. Benzie AA, Bansi LK, Sabin C, et al. Viral rebound in patients on antiretroviral therapy with viral suppression: association with extent of previous virological failure and time with viral suppression [abstract O9]. 12th Annual Conference of the British HIV Association; 2006 29 Mar-1 Apr; Brighton, UK
31. Ledergerber B, Lundgren JD,Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62
32. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised openlabel trials. Lancet 2006; 368: 466-75
33. Cahn P, and the RESIST 2 Study Team. 24-Week data from RESIST 2: Phase 3 study of the efficacy and safety of background therapy plus tipranavir/ritonavir (/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients [abstract PL14.3]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14-18; Glasgow, UK
34. Cooper D, Hicks C, Cahn P, et al. 24-Week study analyses: The efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) [abstract 561]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston, Massachusetts, USA
35. Hicks CB and the RESIST-1 study team. A phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data [abstract 3726]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 31-Nov 2; Washington DC, USA
36. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4 T-cell response to highly active antiretroviral therapy according to baseline CD4 T-cell count. J Acquir Immune Defic Syndr 2004; 36: 702-13
37. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increased in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-15
38. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-95
39. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003; 17: 963-9
40. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 168-75
41. US Department of Labor, Bureau of Labor Statistics. US Medical Care Consumer Price Index; 2008 [online]. Available from URL: Http://data.bls.gov/ cgi-bin/surveymost?cu [Accessed 2009 Dec 10]
42. Tibotec Pharmaceuticals. Results of POWER 1 and 2 Phase II clinical trials for darunavir/r. City: Mechelen, Belgium. Tibotec Pharmaceuticals. Data on file, 2005
43. Maggiolo F, Migliorino M, Pirali A, et al. Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment. J Acquir Immune Defic Syndr 2000; 25: 36-43
44. Yamashita TE, Phair JP, Muñoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15: 735-46
45. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78
46. De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23: 1829-40
47. Cook J, Dasbach E, Coplan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: Application to a clinical trial. AIDS Res Hum Retroviruses 1999; 15: 499-508
48. Medispan. Price-check PC; [online]. Available from URL: Http://www.medispan.com/index.aspx [Accessed 2009Dec 10]
49. Analy Source® Online; [online]. Available from URL: Http://www.analysource.com [Accessed 2009 Dec 10]
50. Yang Z, Norton EC, Stearns SC. Longevity and health care expenditures: The real reasons older people spend more. J Gerontol 2003; 58: S2-10
51. Moeremans K, Annemans L, Löthgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010; 28 Suppl. 1: 107-28
52. Food and Drug Administration (FDA): Press Release: FDA approves darunavir; 2006 Jun 23 [online]. Available from URL: Www.fda.gov/NewsEvents/ Newsroom/PressAnnounce ments/2006/ucm108676.htm [Accessed 2009 Dec 10]
53. European Commission Community register of medicinal products for human use. PREZISTA; [online]. Available from URL: Http://ec.europa.eu/enterprise/ sectors/pharma ceuticals/documents/community-register/html/h380.htm [Accessed 2009 Dec 10]
54. Liu GG, Yin DD, Lyu R, et al. Economic costs of HIV infection: An employer's perspective. Eur J Health Econ 2002; 3: 226-34
55. Sendi P, Schellenberg F, Ungsedhapand C, et al. Productivity costs and determinants of productivity in HIVinfected patients. Clin Ther 2004; 26: 791-800
56. Ahsan N, Langhoff E. Immunopathogenesis of human immunodeficiency virus. Semin Nephrol 1998; 18: 422-35
57. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007; 8: 96-104
58. Simpson KN, Chumney ECG, Hicks CB, et al. Cost effectiveness of tipranavir in treatment-experienced HIV patients in the USA [abstract PIN10]. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2006 May 20-24; Philadelphia, Pennsylvania, USA
59. Hill A, Moyle G. Relative antiviral efficacy of ritonavirboosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-64
60. Simpson KN, Jones WJ, Rajagopalan R, et al. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Invest 2007; 27: 443-52
61. Rockstroh J, Clumeck N, Spinosa-Guzman S, et al. Darunavir (TMC114)/r has tolerability and efficacy benefits for treatment-experienced patients compared with control PIs; overview of the POWER trials [abstract P28]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow, UK
62. Sherman DS, Fish DN. Management of protease inhibitorassociated diarrhea. Clin Infect Dis 2000; 30: 908-14
63. Committee forMedicinal Products for HumanUse (CHMP) of the European Medicines Evaluation Agency (EMEA). Summary of positive opinion for raltegravir; 2007 Nov 27 [online]. Available from URL: Http://www.ema.europa. eu/pdfs/human/press/pr/52210907en.pdf [Accessed 2009 Dec 10]
64. Committee forMedicinal Products for HumanUse (CHMP) of the European Medicines Evaluation Agency (EMEA). Summary of positive opinion for maraviroc; 2007 [online]. Available from URL: Http://www.ema.europa.eu/human docs/Humans/EPAR/celsentri/celsentri.htm [Accessed 2009 Dec 10]
65. Food and Drug Administration (FDA) Press Release. FDA approves new antiretroviral drug; 2007 Oct 16 [online]. Available from URL: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109008.htm [Accessed 2009 Dec 10]
66. Food and Drug Administration (FDA) Press Release. FDA approves novel antiretroviral drug; 2007 Aug 6 [online]. Available from URL: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108960.htm [Accessed 2009 Dec 10]
67. Horne R, Clotet B, Cohen C, et al. Treatment-experienced patient perceptions of self-injectable therapy [abstract PE7.3/25]. 10th European AIDS Clinical Society Conference; 2005 Nov 11-14; Dublin, Ireland
68. Loveday C, MacRae E. Susceptibility of a protease inhibitor (PI) treatment-experienced UK clinical cohort to TMC-114 [abstract PL2.2]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12-16; Glasgow, UK. 2006
69. Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007; 60: 885-8
70. Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: Patterns of occurrence and association with past treatment. J Infect Dis 2007; 196: 1177-9
71. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97
72. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002; 31 (Suppl.): S123-7
73. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviral-naive, HIV-1-infected patients. Antiviral Ther 2003; 8: 339-46
74. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58: 235-42